WO2006109195A3 - Modulation de reponse immunitaire par hemaglutinine filamenteuse - Google Patents

Modulation de reponse immunitaire par hemaglutinine filamenteuse Download PDF

Info

Publication number
WO2006109195A3
WO2006109195A3 PCT/IB2006/001563 IB2006001563W WO2006109195A3 WO 2006109195 A3 WO2006109195 A3 WO 2006109195A3 IB 2006001563 W IB2006001563 W IB 2006001563W WO 2006109195 A3 WO2006109195 A3 WO 2006109195A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune response
modulation
filamentous haemagglutinin
fha
suppression
Prior art date
Application number
PCT/IB2006/001563
Other languages
English (en)
Other versions
WO2006109195A2 (fr
Inventor
Kingston Mills
Brian Keogh
Peter Mcguirk
Kevin Walsh
Original Assignee
Trinity College Dublin
Kingston Mills
Brian Keogh
Peter Mcguirk
Kevin Walsh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trinity College Dublin, Kingston Mills, Brian Keogh, Peter Mcguirk, Kevin Walsh filed Critical Trinity College Dublin
Publication of WO2006109195A2 publication Critical patent/WO2006109195A2/fr
Publication of WO2006109195A3 publication Critical patent/WO2006109195A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Procédé de modulation de réponse immunitaire par administration d'hémaglutinine filamenteuse ou bien de dérivé, mutant, fragment, variant ou peptide correspondant. Il est apparu que l'IL-17 était un médiateur pro-inflammatoire important entraînant une pathologie sous forme de maladie auto-immune. On a démontré que l'hémaglutinine filamenteuse supprimait la production d'IL-23 et d'IL-27. La suppression de ces cytokines supprime à son tour l'expansion clonale des lymphocytes T produisant de l'IL-17. La suppression des lymphocytes en question induit ensuite un abaissement de la production de cytokine IL-17.
PCT/IB2006/001563 2005-04-14 2006-04-18 Modulation de reponse immunitaire par hemaglutinine filamenteuse WO2006109195A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0507561.9A GB0507561D0 (en) 2005-04-14 2005-04-14 Modulation of an immune response by filamentous haemagglutinin
GB0507561.9 2005-04-14

Publications (2)

Publication Number Publication Date
WO2006109195A2 WO2006109195A2 (fr) 2006-10-19
WO2006109195A3 true WO2006109195A3 (fr) 2007-04-05

Family

ID=34611130

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001563 WO2006109195A2 (fr) 2005-04-14 2006-04-18 Modulation de reponse immunitaire par hemaglutinine filamenteuse

Country Status (2)

Country Link
GB (1) GB0507561D0 (fr)
WO (1) WO2006109195A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
EP2892353A4 (fr) * 2012-09-10 2016-10-26 Yeda Res & Dev Thérapie d'immunomodulation individualisée pour des troubles neurodégénératifs, une lésion du snc et la démence liée à l'âge

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034983A1 (fr) * 2003-10-14 2005-04-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Utilisation d'hemagglutinine filamenteuse dans le traitement et/ou la prevention de troubles d'origine immunologique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034983A1 (fr) * 2003-10-14 2005-04-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Utilisation d'hemagglutinine filamenteuse dans le traitement et/ou la prevention de troubles d'origine immunologique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 2004 (2004-04-01), BRAAT HENRI ET AL: "Immuno-modulating effect of filamentous hemagglutinine A of Bordetella pertussis in experimental colitis", XP002413239, Database accession no. PREV200600084431 *
GASTROENTEROLOGY, vol. 126, no. 4, Suppl. 2, April 2004 (2004-04-01), DIGESTIVE DISEASE WEEK/105TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; NEW ORLEANS, LA, USA; MAY 16 20, 2004, pages A284 - A285, ISSN: 0016-5085 *

Also Published As

Publication number Publication date
GB0507561D0 (en) 2005-05-18
WO2006109195A2 (fr) 2006-10-19

Similar Documents

Publication Publication Date Title
NO2018010I1 (no) HPV 31 L1 protein
NZ701614A (en) Endophytes and related methods (4)
MY139500A (en) Optimized expression of hpv 58 l1 in yeast
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
MY140664A (en) Optimized expression of hpv 45 l1 in yeast
ATE507840T1 (de) Hilfszusammensetzung für vakzinen, die über die schleimhaut oder durch injektion verabreicht werden
WO2005089164A3 (fr) Induction de reponses immunitaires cellulaires au papillomavirus humain utilisant des compositions peptidiques et d'acides nucleiques
UA102097C2 (ru) Способ лечения воспалительного заболевания с применением соединения, которое нейтрализует gm-csf, и соединения, которое нейтрализует il-17
WO2006109195A3 (fr) Modulation de reponse immunitaire par hemaglutinine filamenteuse
WO2007099348A3 (fr) Peptide et ses utilisations
EP1790332A4 (fr) Vaccin pour administration orale
WO2004037175A3 (fr) Compositions et methodes pour traiter une maladie a mediation par le papillomavirus humain (hpv)
CO6592086A2 (es) Metodo para producir proteinas de interferon recombiantes solubles sin desnaturalizacion
MX2007013472A (es) Vacuna.
BRPI0409432A (pt) processo para preparação de óxido de propileno
WO2010111586A3 (fr) Immunisation par voie muqueuse
EP1591520A3 (fr) Microorganisme dans lequel le gène tyrR a été inactivé, méthode pour produire ledit microorganisme et procédé de production de L-thréonine utilisant ledit microorganisme
AU2003260452A1 (en) Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
WO2009027478A3 (fr) Procédé d'élimination de conservateurs à partir d'une préparation pharmaceutique liquide
WO2007008093A3 (fr) Procede permettant de fabriquer un vaccin recombine contre la maladie hemorragique virale du lapin, vaccin et application d'un antigene recombine dans la fabrication du vaccin
WO2002069985A3 (fr) Potentialisation de reponse immunitaire
WO2004083390A3 (fr) Calicivirus felin systemique virulent
TW200607858A (en) Optimized expression of HPV 31 L1 in yeast
TW200519421A (en) Manufacturing method of ball microlens for image sensor
WO2007047763A3 (fr) Vaccins bcr-abl et leurs methodes d'utilisation

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06765511

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06765511

Country of ref document: EP

Kind code of ref document: A2